Related references
Note: Only part of the references are listed.Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: Results from American College of Surgeons Oncology Group trials Z0010 and Z0011
John A. Olson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Patients with breast cancer are unlikely to benefit from prophylactic irradiation of the contralateral breast - Reply
David J. Brenner et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Challenges and pitfalls of combining targeted agents in phase I studies
Stephen A. Cannistra
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Opportunities and obstacles to combination targeted therapy in renal cell cancer
Jeffrey A. Sosman et al.
CLINICAL CANCER RESEARCH (2007)
Vascular endothelial growth factor in breast cancer: Biologic and therapeutic aspects
GW Sledge
SEMINARS IN ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
